CA2584209A1 - Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof - Google Patents

Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof Download PDF

Info

Publication number
CA2584209A1
CA2584209A1 CA002584209A CA2584209A CA2584209A1 CA 2584209 A1 CA2584209 A1 CA 2584209A1 CA 002584209 A CA002584209 A CA 002584209A CA 2584209 A CA2584209 A CA 2584209A CA 2584209 A1 CA2584209 A1 CA 2584209A1
Authority
CA
Canada
Prior art keywords
group
alkenyl
heteroaryl
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002584209A
Other languages
English (en)
French (fr)
Inventor
Chong-Sheng Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Atomics Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2584209A1 publication Critical patent/CA2584209A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
CA002584209A 2004-10-13 2005-10-13 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof Abandoned CA2584209A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/964,236 US7517887B2 (en) 2003-04-09 2004-10-13 Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US10/964,236 2004-10-13
PCT/US2005/036890 WO2006044573A2 (en) 2004-10-13 2005-10-13 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof

Publications (1)

Publication Number Publication Date
CA2584209A1 true CA2584209A1 (en) 2006-04-27

Family

ID=36203526

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002584209A Abandoned CA2584209A1 (en) 2004-10-13 2005-10-13 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof

Country Status (6)

Country Link
US (1) US7517887B2 (cg-RX-API-DMAC10.html)
EP (1) EP1799682B1 (cg-RX-API-DMAC10.html)
JP (2) JP5270163B2 (cg-RX-API-DMAC10.html)
AU (1) AU2005295704A1 (cg-RX-API-DMAC10.html)
CA (1) CA2584209A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006044573A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156889A1 (en) * 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7517887B2 (en) 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
TW200523262A (en) * 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
CN101253173A (zh) * 2005-09-02 2008-08-27 辉瑞有限公司 羟基取代的1h-咪唑并吡啶和方法
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008145159A1 (de) * 2007-05-30 2008-12-04 Sarstedt Aktiengesellschaft & Co. Eine blutentnahmevorrichtung umfassend komponenten zur stabilisierung des homocysteinspiegels und/oder zur hemmung der fortlaufenden bildung von homocystein in blutproben, serumproben oder blutplasmaproben
CN101456860B (zh) 2007-12-10 2011-02-16 中国科学院上海药物研究所 4-[9-(6-氨基嘌呤基)]-2(s)-羟基丁酸甲酯的制备方法
TWI386204B (zh) * 2008-04-10 2013-02-21 Mitsubishi Tanabe Pharma Corp 高半胱胺酸合成酶抑制劑
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2011043480A1 (ja) * 2009-10-09 2011-04-14 田辺三菱製薬株式会社 ホモシステイン合成酵素阻害薬
CN117045661B (zh) * 2023-10-11 2024-01-30 广东医科大学附属医院 Sahh可逆型抑制剂的应用、药物组合物及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE756914A (fr) * 1969-10-25 1971-03-30 Fujisawa Pharmaceutical Co Nouveaux derives de l'adenine et leurs sels
SE8404768L (sv) * 1983-09-27 1985-03-28 Ceskoslovenska Akademie Ved 9-(aminoalkyl)-8-hydroxiadeniner och sett for deras framstellning
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
JPH0374330A (ja) * 1989-08-11 1991-03-28 Snow Brand Milk Prod Co Ltd 脱髄疾患治療剤
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US6020337A (en) * 1993-04-05 2000-02-01 Cell Therapeutics, Inc. Electronegative-substituted long chain xanthine compounds
AU677851B2 (en) 1993-06-21 1997-05-08 Merrell Pharmaceuticals Inc. Novel carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
JP2000502682A (ja) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US5668173A (en) 1996-02-23 1997-09-16 The Board Of Trustees Of The University Of Illinois Corp. Method of increasing the conversion of homocysteine to methionine and uses thereof
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
WO1998007421A1 (en) * 1996-08-16 1998-02-26 Ishihara Sangyo Kaisha, Ltd. Medicinal composition
BR9808845A (pt) * 1997-03-14 2000-08-01 Otsuka Pharma Co Ltd Derivado de pirimidina, agentes para a cura de uma doença alérgica, da asma e de uma dermatite atópica, agentes para inibição da produção de no de tnf-alfa, de citoquinas e da 5-lipoxigenase, processos para curar uma doença alérgica, a asma e uma dermatite atópica e para inibir a produção de no, de tnf-alfa e de citoquinas e a 5-lipoxigenase e usos de um composto
EP0969743B1 (en) 1997-03-20 2004-09-15 Coventry Group, Ltd. Nutritional supplement for cardiovascular health
US5854023A (en) 1997-07-17 1998-12-29 Incyte Pharmaceuticals, Inc. Polynucleotides encoding human S-adenosyl-5-homocysteine hydrolase derived from bladder
US6066467A (en) 1997-07-24 2000-05-23 Anticancer, Inc. High specificity homocysteine assays for biological samples
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
DE69829875T2 (de) * 1997-10-14 2006-03-09 Mitsubishi Pharma Corp. Piperazin-verbindungen und ihre medizinische verwendung
GB9724838D0 (en) * 1997-11-26 1998-01-21 Franks Christopher R Compositions
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
US5962274A (en) 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
KR100589474B1 (ko) * 1998-03-26 2006-06-14 산텐 세이야꾸 가부시키가이샤 신규한 우레아 유도체
US6127381A (en) * 1998-04-28 2000-10-03 Basu; Amaresh Isoquinoline compound melanocortin receptor ligands and methods of using same
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
US6323188B1 (en) 1998-07-01 2001-11-27 Donald L. Weissman Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins
US6210686B1 (en) 1998-12-18 2001-04-03 Beth Israel Deaconess Medical Center Dietary supplement and method for lowering risk of heart disease
US6274170B1 (en) 1999-02-18 2001-08-14 Richard Heibel Compounds for cardiovascular treatment comprising multi-vitamin and anti-platelet aggregating agents and methods for making and using the same
WO2000064479A1 (en) 1999-04-27 2000-11-02 Antibody Systems, Inc. Compositions containing tetracyclines for treating hemorrhagic virus infections and other disorders
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US6361800B1 (en) 2000-04-13 2002-03-26 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6337317B1 (en) * 2000-06-27 2002-01-08 The University Of British Columbia Antimicrobial peptides and methods of use thereof
WO2003103584A2 (en) * 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
US7517887B2 (en) 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7196093B2 (en) 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156889A1 (en) * 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof

Also Published As

Publication number Publication date
JP2012197314A (ja) 2012-10-18
WO2006044573A2 (en) 2006-04-27
EP1799682A4 (en) 2009-11-04
US7517887B2 (en) 2009-04-14
JP2008515994A (ja) 2008-05-15
US20050182075A1 (en) 2005-08-18
WO2006044573A3 (en) 2006-06-15
EP1799682A2 (en) 2007-06-27
EP1799682B1 (en) 2012-12-05
JP5270163B2 (ja) 2013-08-21
AU2005295704A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
US20080171049A1 (en) Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
JP2012197314A (ja) Ｓ−アデノシル−ｌ−ホモシステイン加水分解酵素の可逆的阻害剤およびその使用
Cronstein et al. Methotrexate and its mechanisms of action in inflammatory arthritis
Liang et al. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review
ES2618489T3 (es) Composiciones farmacéuticas combinadas y usos de las mismas
JP2021063091A (ja) ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
ES2677874T3 (es) Tratamiento del cáncer con inhibidores de la cinasa TOR
ES2678250T3 (es) Tratamiento del cáncer con inhibidores de quinasa TOR
US20080194594A1 (en) Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus
Saleh et al. Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells
US11369602B2 (en) Use of tadalafil as protein arginine methyltransferase (PRMT5) inhibitor
US20220267270A1 (en) Sting modulators, compositions, and methods of use
Fang et al. Enzymatic-related network of catalysis, polyamine, and tumors for acetylpolyamine oxidase: from calculation to experiment
CN114174269B (zh) 作用于egfr和erbb2的嘧啶类化合物
Demirag et al. Molecular docking analysis of used drugs for the treatment of cancer
Wang et al. Design, synthesis, and mechanism study of novel BMX inhibitors based on the core of 1, 3, 5-triazin-2-amine for the treatment of gastric carcinoma
Filiberti et al. Pegylation approach applied to erlotinib–carbonic anhydrase inhibitors hybrids towards anticancer agents
Cole et al. Antimetabolites: A new perspective
Vermani et al. New inhibitors of p38 mitogen-activated protein kinase: Repurposing of existing drugs with deep learning
Sousa Targeting cancer-related proteins: Rational design of covalent inhibitors and degraders for TEC kinases and serine hydrolases
Thiagalingam The road to precision cancer therapy–history and strategies
EA053183B1 (ru) Способ лечения острого миелоидного лейкоза и миелодиспластических синдромов при помощи ингибиторов внутриклеточных путей регуляции иммунных контрольных точек, химическое соединение и способы его синтеза
Cmiljanović Development of Novel, Potent and Selective Small Molecular Weight PI3K/mTOR Inhibitors for the Treatment of Cancer
Valente et al. Potential of Pyrimidine Metabolism for Antitrypanosomal Drug Discovery
WO2018175302A1 (en) Polymer conjugates targeting c-src with reduced exposure

Legal Events

Date Code Title Description
FZDE Discontinued